Page last updated: 2024-11-04

clotiazepam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clotiazepam: was heading 1975-94 (see under AZEPINES 1978-90; was Y 6047 see under AZEPINES 1975-77); Y 6047 was see CLOTIAZEPAM 1978-94; use AZEPINES to search CLOTIAZEPAM 1975-94; thienodiazepine derivative with actions similar to those of benzodiazepines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-carene: a monoterpene; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2811
CHEMBL ID1697737
CHEBI ID31425
SCHEMBL ID44592
MeSH IDM0224719
PubMed CID79044
CHEMBL ID2286984
CHEBI ID184750
MeSH IDM0224719

Synonyms (54)

Synonym
2h-thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-
clotiazepam
rize
y-6047 ,
distensan
rizen
5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2h-thieno[2,3-e][1,4]diazepin-2-one
DB01559
D01328
33671-46-4
clotiazepam (jp17/inn)
rize (tn)
rise
5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2h-thieno(2,3-e)-1,4-diazepin-2-one
dea no. 2752
einecs 251-627-3
brn 0623332
clotiazepam [inn:jan]
y 6047
5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2h-thieno(2,3-e)(1,4)diazepin-2-one
2h-thieno(2,3-e)(1,4)diazepin-2-one, 1,3-dihydro-5-(o-chlorophenyl)-7-ethyl-1-methyl-
2h-thieno(2,3e)(1,4)-diazepin-2-one, 5-(o-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-
trecalmo
clotiazepamum [inn-latin]
AKOS005065735
5-(2-chlorophenyl)-7-ethyl-1-methyl-3h-thieno[2,3-e][1,4]diazepin-2-one
CHEMBL1697737
tienor
unii-zcn055599v
zcn055599v ,
clotiazepamum
veratran
clozan
clotiazepam [mart.]
clotiazepam [who-dd]
clotiazepam [jan]
clotiazepam [inn]
clotiazepam [mi]
SCHEMBL44592
2h-thieno[2,3-e]-1,4-diazepine-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-
DTXSID0022852
5-(2-chlorophenyl)-7-ethyl-1-methyl-1h,2h,3h-thieno[2,3-e][1,4]diazepin-2-one
CHEBI:31425
CS-7319
HY-U00317
Q2263999
clotiazepam, 1mg/ml in methanol
2-carene
3,7,7-trimethylbicyclo[4.1.0]hept-2-ene
CHEBI:184750
4,7,7-trimethylbicyclo[4.1.0]hept-4-ene
AKOS025295339
CHEMBL2286984
DTXSID00858821
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID688286Allosteric modulation of gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current at 0.1 to 500 uM by voltage clamp analysis relative to control2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Identification and characterization of GABA(A) receptor modulatory diterpenes from Biota orientalis that decrease locomotor activity in mice.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID688292Allosteric modulation of gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current by voltage clamp analysis2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Identification and characterization of GABA(A) receptor modulatory diterpenes from Biota orientalis that decrease locomotor activity in mice.
AID603955In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID611614Allosteric modulation of gamma-aminobutyric acid receptor A alpha1beta2gamma2S expressed in Xenopus oocytes assessed as potentiation of GABA-mediated chloride current at 1 uM by voltage clamp assay2011Journal of natural products, Jun-24, Volume: 74, Issue:6
Positive GABA(A) receptor modulators from Acorus calamus and structural analysis of (+)-dioxosarcoguaiacol by 1D and 2D NMR and molecular modeling.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1111620Insecticidal activity against adult Sitophilus zeamais assessed as mortality measured daily for 1 week by fumigation assay2011Pest management science, Jun, Volume: 67, Issue:6
Composition of essential oil of Chinese Chenopodium ambrosioides and insecticidal activity against maize weevil, Sitophilus zeamais.
AID1111619Contact toxicity against adult Sitophilus zeamais assessed as mortality applied to dorsal thorax of insect measured daily for 1 week2011Pest management science, Jun, Volume: 67, Issue:6
Composition of essential oil of Chinese Chenopodium ambrosioides and insecticidal activity against maize weevil, Sitophilus zeamais.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (16.00)18.2507
2000's7 (28.00)29.6817
2010's13 (52.00)24.3611
2020's1 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.26 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index143.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (83.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (11.11%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Reviews1 (11.11%)6.00%
Case Studies6 (33.33%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (50.00%)84.16%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]